Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs is dedicated to enhancing research and discovery by offering the highest quality recombinant products at exceptional prices. Our commitment goes beyond just providing outstanding products; we also deliver superior technical assistance to ensure that our customers receive the support they need throughout their research journey. By prioritizing quality and affordability, we aim to empower scientists and institutions to achieve impactful results, driving innovation and progress in the biomedical field.
CD40 is a transmembrane protein that plays a crucial role in the immune system. It is expressed on various immune cells such as B cells, dendritic cells, and macrophages. The interaction of CD40 with its ligand, CD40L, triggers a series of intracellular signaling events that regulate immune responses. Studying CD40 is of great significance as it helps in understanding the mechanisms of immune activation and regulation. Insights into CD40 can lead to the development of novel therapeutic strategies for immune-related disorders like autoimmune diseases and cancer. It also provides potential targets for drug development to modulate the immune system and improve treatment outcomes.
CD40 molecule; p50; Bp50; CDW40; TNFRSF5
Predicted to enable antigen binding activity; protein domain specific binding activity; and ubiquitin protein ligase binding activity. Involved in B cell mediated immunity; CD40 signaling pathway; and cellular calcium ion homeostasis. Acts upstream of or within several processes, including defense response to other organism; positive regulation of B cell activation; and positive regulation of interleukin-12 production. Located on the external side of the plasma membrane and intracellular membrane-bounded organelle. Part of CD40 receptor complex. Is expressed in several structures, including alimentary system; brain; hemolymphoid system gland; liver and biliary system; and reproductive system. Human ortholog(s) of this gene implicated in several diseases, including Kawasaki disease; autoimmune disease (multiple); end stage renal disease; hyperimmunoglobulin syndrome (multiple); and non-Hodgkin lymphoma (multiple). Orthologous to human CD40 (CD40 molecule).
In order to fulfill the research and development requirements of researchers and expedite the advancement of clinical research on CD40, our company offers developers antibody products of high quality and stability.
Cat. No. | Product Name | Target Species | Host Species | Applications |
TAB-126CL | Human Anti-CD40 Recombinant Antibody | Human | Human | Block; Cyt; FuncS; Inhib |
TAB-201LC | Mouse Anti-CD40 Recombinant Antibody | Human; Rhesus | Mouse | ELISA; FC; Inhib; FuncS |
TAB-152 | Anti-Human CD40 Recombinant Antibody (Dacetuzumab) | Human | Human | IF; IP; Neut; FuncS; ELISA; FC; ICC |
TAB-470CQ | Anti-Human CD40 Recombinant Antibody (Selicrelumab) | Human | Human | ELISA; IHC; FC; IP; IF; FuncS |
HPAB-A1257-YJ | Human Anti-CD40 Recombinant Antibody | Human | Human | ELISA |
We aim to accelerate the advancement of biopharmaceutical research and development to commercialization. To satisfy customers' requirements for antibody products of high quality and standard, we have formulated a set of rigorous production management regulations to manufacture satisfactory products for customers, thus helping them save time and effort in the research and development of related drugs.
Fig.1 SDS-PAGE analysis of anti-CD40 antibody
(Cat# TAB-126CL, Creative Biolabs).
Fig.2 SEC-HPLC analysis of anti-CD40 antibody
(Cat# TAB-126CL, Creative Biolabs).
Fig.3 ELISA analysis of anti-CD40 antibody
(Cat# TAB-201LC, Creative Biolabs).
Fig.4 WB analysis of anti-CD40 antibody
(Cat# TAB-201LC, Creative Biolabs).
Fig.5 DB analysis of anti-CD40 antibody
(Cat# TAB-201LC, Creative Biolabs).
Our serum-free mammalian cell expression platform delivers all-in-one services, starting from gene synthesis and ending with the manufacture of high-quality recombinant antibodies at the milligram-to-gram scale. Creative Biolabs provides high-level services and high-quality products for all researchers in the biomedical industry.
Featured Anti-CD40 Recombinant Antibody Production Platforms
Fig.6 Milligram-scale recombinant antibody production.
Fig.7 Gram-scale recombinant antibody production.
To meet the diverse needs of customers during their scientific research, we provide customers with a wide range of high-quality antibody products, including but not restricted to Fab, scFv, etc.
Fig.8 Full Length Anti-CD40 Recombinant Antibody Production and Modalities.
Table 1. Therapeutic approaches targeting CD40 in clinical development.
Research phase | Company | Classification | Indications | Details |
Phase II | Biocytogen | Biologics | Cancer | It is a humanized monoclonal antibody against human CD40. |
Phase II | Kiniksa Pharmaceuticals | Biologics | Autoimmune disease | It is a monoclonal antibody inhibitor of CD40 signaling in phase II clinical trials at Kiniksa Pharmaceuticals for the treatment of rheumatoid arthritis. |
Phase II | AbbVie | Biologics | Cancer | This is an agonistic anti-CD40 monoclonal antibody being developed by AbbVie for the intravenous treatment of advanced solid tumors, including metastatic pancreatic cancer. |
Phase II | AbbVie | Biologics | Crohn's disease | It is a biological agent directed against CD40 in phase II clinical development at AbbVie for the treatment of ulcerative colitis. |
Phase II | Seagen | Biologics | Cancer | It is an afucosylated antibody targeting CD40 in phase II clinical development at Seagen (formerly, Seattle Genetics) for the treatment of melanoma and metastatic non-squamous non-small cell lung cancer (NSCLC). |
Phase II | Fast Forward Pharmaceuticals | Biologics | Crohn's disease | This is a monoclonal antibody against CD40, is in phase II clinical trials at Fast Forward Pharmaceuticals for the treatment of patients with primary biliary cirrhosis and Crohn's disease. |
Phase II | Novartis | Biologics | Diabetes type 1 | This is an anti-CD40 monoclonal antibody in phase II clinical development at Novartis for the treatment of primary Sjögren's syndrome, systemic lupus erythematosus, hidradenitis suppurativa and type 1 diabetes mellitus. |
Phase II | AbbVie | Biologics | Immunological Disorders | It is in phase II clinical trials at Boehringer Ingelheim for the treatment of lupus nephritis. |
Phase II | Apexigen | Biologics | Cancer | This is a humanized monoclonal antibody targeting CD40, is in phase II clinical development at Pyxis Oncology (former Apexigen) for the treatment of advanced soft tissue sarcomas in combination with doxorubicin, and for the treatment of unresectable or metastatic melanoma. |
Phase I/II | BioNTech | Biologics | Cancer | It is a humanized bispecific monoclonal antibody targeting CD40 and CD137 (4-1BB). |
Phase I/II | Alligator Bioscience | Biologics | Cancer | This is a human monoclonal antibody against the CD40 receptor in early clinical development. |
Phase I/II | Bellicum Pharmaceuticals | Biologics | Cancer | This is a cancer vaccine candidate consisting of AP1903-inducible dendritic cells (DCs) transduced with an adenovector encoding iCD40. |
Phase I/II | Fast Forward Pharmaceuticals | Biologics | Arthritis | It is a human anti-CD40 antagonist antibody that had been in early clinical trials at PanGenetics for the treatment of psoriatic arthritis and Crohn's disease. |
Phase I/II | Genentech | Biologics | Cancer | It is a chimeric humanized anti-CD40 monoclonal antibody with apoptosis-inducing properties that had been in early clinical development by originator Seattle Genetics (now Seagen) for the treatment of multiple myeloma. |
Phase I | Syncromune | Combinations | Cancer | This is an immunotherapy candidate that combines partial tumor oncolysis with a fixed-dose combination multi-target biologic drug to provide a novel, personalized therapeutic approach. |
Phase I | Biosion | Biologics | Cancer | This is a humanized monoclonal agonist antibody targeting CD40. |
Phase I | Beijing Mabworks Biotech | Biologics | Cancer | It is a humanized agonistic monoclonal antibody targeting CD40 in early clinical development at Beijing Mabworks Biotech for the treatment of advanced or metastatic solid tumors. |
Phase I | Biocytogen | Biologics | Cancer | This is a PD-1/CD40 bispecific antibody in phase I clinical development at Chipscreen Biosciences for the treatment of patients with advanced solid tumors. |
If you would like to learn more about our CD40 antibody products or have any specific inquiries, please don't hesitate to reach out to us. Our dedicated team is ready to assist you and provide the information you need, ensuring a positive experience as you pursue your research goals.